This article, written with co-authors Bruce H. Kobayashi, Joshua D. Wright, and Douglas H. Ginsburg, examines the economics of litigation and settlement of patent disputes arising from Paragraph IV Abbreviated New Drug Application (ANDA) filings under the Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman Act) within the framework set out in Actavis.
Merger enforcement policies of the second Trump Administration: Early developments and priorities
In the article published by the American Bar Association (ABA), “Merger Enforcement Policies of the Second Trump Administration: Early Developments and...